McCredie D A, Powell H R, Rotenberg E
Br J Urol. 1976 Apr;48(2):93-100. doi: 10.1111/j.1464-410x.1976.tb02988.x.
4 patients with nephrocalcinosis were treated with disodium ethane 1-hydroxy-1, 1-diphosphonate (EHDP) for a period of 13 months. No clinical side-effects were observed and growth proceeded normally. Radiographic changes of osteitis fibrosa cystica developed in 1 child and bone biopsy in 2 children showed defective osteoid mineralisation. It is suggested that EHDP prevented further crystal deposition in 3 children but did not prevent non-calcium stone formation in the 4th child. In view of this and the development of histological and radiographic evidence of osteomalacia and/or secondary hyperparathyroidism in these patients the value of EHDP remains dubious. On the other hand its use may be justified when rapidly increasing calcification is expected, as for example in hyperoxaluria.
4例肾钙质沉着症患者接受1-羟基-1,1-二磷酸乙烷二钠（EHDP）治疗13个月。未观察到临床副作用，生长发育正常。1例儿童出现纤维囊性骨炎的影像学改变，2例儿童的骨活检显示类骨质矿化缺陷。提示EHDP阻止了3例儿童进一步的晶体沉积，但未阻止第4例儿童非钙结石的形成。鉴于此，以及这些患者出现了骨软化症和/或继发性甲状旁腺功能亢进的组织学和影像学证据，EHDP的价值仍值得怀疑。另一方面，当预期会迅速增加钙化时，例如在高草酸尿症中，使用EHDP可能是合理的。
